Top oncology conference is coming! Multiple popular anti-cancer drugs will debut, involving these A-share companies.
①The annual meeting of the European Society for Medical Oncology will be held in Barcelona, Spain in 2024; ②At the meeting, Beigene, Jiangsu Hengrui Pharmaceuticals and other listed companies will release the latest data on their oncology drugs; ③In addition, the conference will also discuss cutting-edge topics such as the impact of artificial intelligence on the diagnosis and treatment of tumors.
Is the GLP-1 pipeline progressing slowly? Gan & Lee Pharmaceuticals: GZR18 has the potential for superior weight reduction efficacy compared to multi-target drugs | Live coverage of the earnings conference.
At the earnings conference, the management of Gan & Lee Pharmaceuticals emphasized that the price regression of the company's insulin products in the follow-up volume procurement has driven the performance. In the face of doubts about the progress of GLP-1 pipeline research and competitiveness, Dou Kai, the General Manager of Gan & Lee Pharmaceuticals, stated that GZR18 injection has a weight loss effect that exceeds exenatide and dulaglutide, and has the potential to be superior to multi-target GLP-1RA drugs in weight loss efficacy.
Zhejiang Hisun Pharmaceutical: Give up the pharmaceutical distribution raw material business, leading to a decline in H1 revenue. Sales of Olsalazine increased significantly compared to the same period last year.
①At the earnings conference, the CFO of Zhejiang Hisun Pharmaceutical explained that the decline in H1 revenue was due to the company's abandonment of low-margin pharmaceutical distribution raw material business and other factors. ②President Xiao Weihong addressed questions about the growth in endocrine drug revenue and the future business model of the animal health sector.
Dongpeng Beverage's performance in the first half of the year reached the upper limit of the forecast, intending to distribute a mid-term cash dividend of approximately 1 billion yuan. Interpretations
In the first half of the year, Dongpeng Beverage's revenue and net income increased by over 40% year-on-year, with net income reaching the upper limit of the previous forecast. The company plans to distribute a cash dividend of 25 yuan for every 10 shares.
Foshan Haitian Flavouring and Food's H1 performance growth rate basically meets the annual plan. The online growth rate is higher than the offline growth rate.|Interpretation of financial report
①"Jiang Mao" Foshan Haitian Flavouring and Food is regaining growth, achieving double growth in performance in the first half of the year after experiencing a double decline in revenue and net profit last year. ②According to a reporter from Cailian Press, online sales of condiments in the first half of the year may be better than the overall large cap market, and the condiment market is presenting structural opportunities, with the increasing importance of the online market.
The decline in the pharmaceutical sector is affecting overall revenue. Fosun Pharma: Will focus on building super 1 billion yuan big varieties | Earnings conference highlights.
Fosun Pharma's revenue from innovative drugs in the first half of the year exceeded 3.7 billion yuan, accounting for about 18% of the overall revenue. Wu Yifang revealed that the business of innovative drugs will strive to achieve a compound annual growth rate of 30% in the next few years. Wu Yifang said that the privatization of Henlius is currently underway, and the entire business and pipeline of Henlius will be deeply integrated with Fosun Pharma through privatization.